What Is an API in Pharma? Meaning, Label Check, Buyer Test

An API, short for active pharmaceutical ingredient, is the part of a medicine that acts on disease or on the body. US federal regulation defines it as "any substance that is intended for incorporation into a finished drug product and is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body" (21 CFR 207.1).

Two points follow from that wording:

• Function defines an API, not origin. FDA's ICH Q7 guidance lists chemical manufacturing, animal sources and plant extraction as routes to an API (ICH Q7). ICH is the International Council for Harmonisation.
• Other names for the same thing. The same regulation says "bulk drug substance" means the same as API. The related term "drug substance" is defined in 21 CFR 314.3 and "does not include intermediates used in the synthesis of such ingredient."

The abbreviation has a second life outside medicine. In a drug context, API means active pharmaceutical ingredient. Software sources such as openFDA use the same letters for application programming interface.

Ask what role the material plays and where it sits in the chain from raw material to patient. Each term in the table below has a test you can run on a label or a supplier document.

Formulation is the recipe and process that turn an API plus excipients into a drug product. Manufacturing an API and formulating a drug product are separate jobs, often done by different companies at different sites.

No. An API is one component, and the product around it varies widely. We tested this on public FDA data. FDA's Drug Facts label format has a line for inactive ingredients, described as "Substances such as binders, colors or flavorings" (FDA, OTC Drug Facts Label).

Our method. Data are from the openFDA drug label endpoint, last updated 2 October 2026.

1. We ran this search: openfda.substance_name:"ACETAMINOPHEN" AND openfda.product_type:"HUMAN OTC DRUG" AND _exists_:inactive_ingredient AND _exists_:active_ingredient. It returned 2,715 labels, which we downloaded 100 at a time.
2. We kept labels whose openfda.substance_name is exactly ACETAMINOPHEN and whose active_ingredient text matches "acetaminophen 500 mg", ignoring case and spacing. That left 340 labels.
3. We lowercased each inactive-ingredient text and removed the "inactive ingredients" prefix, asterisks and any "may contain" clause. We then split it into names at commas, semicolons and "and". Three labels yielded no parsable list, which left 337 labels from 167 labelers.

What we found:

• The 337 labels show 106 distinct inactive-ingredient lists, with a median of 9 inactive ingredients per label (range 2 to 25).
• No single excipient appears on all 337 labels.
• The most common are stearic acid (269 labels, 80%), povidone (262, 78%), pregelatinized starch (239, 71%), sodium starch glycolate (237, 70%) and hypromellose (232, 69%).

Two limits apply. The data are label text, not amounts. Different spellings of the same excipient count separately, so 106 is an upper bound. Repackaged products can repeat another label's list, so we counted labels, not unique formulations.

One kilogram of API makes 2,000 tablets at 500 mg of API per tablet, before any process loss. This is our model, not an official figure.

Tablets = (kg of API × 1,000,000 mg/kg) ÷ mg of API per tablet. It assumes no overage and no process loss.

• At 500 mg per tablet: (1 × 1,000,000) ÷ 500 = 2,000 tablets.
• At 50 micrograms (0.05 mg) per tablet: (1 × 1,000,000) ÷ 0.05 = 20,000,000 tablets.

Real batches need more API than this, and each tablet carries its excipients on top of the API weight.

GMP rules for making an API apply from the point where the defined API starting material enters the process. FDA's ICH Q7 guidance states that it "does not apply to steps prior to the introduction of the defined API starting material" (ICH Q7, September 2016, nonbinding recommendations).

For a chemically made API, the sequence runs:

1. Production of the starting material.
2. Introduction of the starting material into the process.
3. Production of intermediates.
4. Isolation and purification.
5. Physical processing and packaging.

The guidance says GMP stringency "should increase as the process proceeds" toward purification and packaging. It also covers physical processing such as granulation, coating, milling and micronizing.

The practical point is that a material sold as an "intermediate" has by definition not reached the API stage. When a supplier quotes a molecule, ask which step the batch represents.

APIs are made by dedicated API manufacturers, by integrated drugmakers that also make finished tablets, and by contract manufacturers (CDMOs, contract development and manufacturing organizations). Distributors and sourcing partners sell them without necessarily making them. For India as an origin, see our guide to Indian pharmaceutical API suppliers.

US rules attach to the manufacturing site, not the seller:

• Foreign establishments that manufacture APIs for the US must register with FDA and list their API, and the listing provided at import must be the manufacturer's own (FDA, Importing APIs).
• Compounding pharmacies must source API from FDA-registered facilities and obtain valid certificates of analysis (FDA, compounders).

No. A drug master file (DMF) is a confidential submission to FDA, and FDA's guideline states: "A DMF IS NEVER APPROVED OR DISAPPROVED." FDA reviews a DMF only when an IND (investigational new drug) sponsor, an applicant for an NDA (new drug application), ANDA (abbreviated new drug application, for generics) or export application, or another DMF holder incorporates it by reference (FDA DMF guideline). A Type II DMF is the type that covers a drug substance, its intermediates and materials used to make them, or a drug product.

Our count. We counted entries in FDA's DMF list for the second quarter of 2026 (current as of 21 July 2026). It holds 41,253 entries, of which 15,541 are active Type II DMFs held by 2,276 distinct holders. We matched the subject line by keyword:

Keyword matching also catches salts, some intermediates and a few drug-product filings, so treat these as indicative counts. The DMF holder is not necessarily the manufacturing site.

The pattern is the useful part. Many separate holders file DMFs for one molecule. In our view, the molecule alone tells you little, so check which site makes your batch. The same list is the nearest public "API drug list": search the subject column for a molecule.

Run six tests on any API offer. Each has a pass and a fail.

1. Do the name and CAS number match everywhere?
   • CAS is the Chemical Abstracts Service registry number.
   • Pass: product name, CAS number and salt or ester form are identical on the quotation, the certificate of analysis (COA) and the safety data sheet (SDS).
   • Fail: any difference, or no CAS number.
2. Is a grade named?
   • Pass: a pharmacopeial standard is named and the COA reports results against its limits. A pharmacopeial standard is a published quality specification such as the United States Pharmacopeia (USP).
   • Fail: "pharma grade" with no standard.
3. Is the COA for your batch?
   • Pass: the batch number on the COA equals the container label, and identity, assay (strength) and purity results are present.
   • Fail: a generic or sample COA.
4. Is the manufacturing site named?
   • Pass: the site and address are given. For US use, you can confirm its FDA registration and listing.
   • Fail: only a trading company is named.
5. If your filing needs a DMF reference, is there a number?
   • Pass: a DMF number and holder that appear on FDA's list as active, Type II, with a matching subject.
   • Fail: "approved DMF" with no number. Our steroid APIs fail this test, because we do not provide DMF support for them.
6. Is it the final API, and is your end use permitted?
   • Pass: the material is described as the final API rather than an intermediate, and its status for your destination and use (human pharmaceutical, veterinary or research) is confirmed in writing.
   • Fail: ambiguity on either point.

Both classes face specific US rules, and a buyer needs to check them before ordering.

• Anabolic steroids. As of October 2026, anabolic steroids, including nandrolone and testosterone, are listed as Schedule III controlled substances in 21 CFR 1308.13(f). Schedule III covers substances with a potential for abuse lower than Schedules I and II (DEA Diversion Control). Importing a non-narcotic Schedule III substance requires registration under the Controlled Substances Act and a filed import declaration, or a permit for some substances, for each shipment (21 CFR 1312.11). Confirm current requirements with DEA Diversion Control before ordering.
• GLP-1 peptide APIs. As of 1 October 2026, FDA states that it "has established a green list import alert (66-80) to help stop GLP-1 active pharmaceutical ingredients (APIs) that have potential quality concerns from entering the U.S. supply chain." FDA adds that the action "does not stop the legal importation into the U.S. market of GLP-1 APIs from compliant API manufacturers" (FDA, concerns with unapproved GLP-1 drugs). GLP-1 is the drug class that includes semaglutide and tirzepatide.

We ask for the details a quotation needs, then confirm the rest product by product. Aarise Pharmaceuticals, an India-based API supplier, sourcing partner, distributor and exporter, publishes this page.

Send us the API name and CAS number, quantity, destination, grade or purity, documents needed, payment terms and Incoterms (the international trade terms that set delivery responsibilities). We quote from the current rate for that product. Minimum order quantity, capacity and lead time vary by product and approved manufacturing source, so we confirm them in the quotation. Available documents may include the COA, specifications and SDS where applicable. Sample and evaluation quantities are available to qualified B2B buyers, with quantity, price and documents confirmed per product.

As of October 2026, standard payment for international commercial orders is generally 100% advance by bank transfer unless other terms are agreed in writing for a specific transaction.

We do not provide DMF, CPP or CEP support for steroid APIs. CPP is a certificate of pharmaceutical product, and CEP is a certificate of suitability to the European Pharmacopoeia monographs. If your filing needs a DMF reference for another API, tell us at enquiry and we will confirm availability for that product.

Our peptide APIs are supplied as bulk raw powder for B2B requirements, not finished vials. Our API supply is for export and institutional use, not consumer sale. Regulatory status and permitted end use are set per molecule, manufacturer documentation and destination rules. Some materials are controlled, veterinary-specific or research-only, and buyers confirm local registration and import authorization before commercial supply.

Prices are quoted per product on request. To start, request a quotation through our US pharma raw material catalog, or contact sunil@aarisepharma.com or WhatsApp +91 9899783330.